Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REALISE: Long-Term Safety of Viaskin Peanut in Peanut-Allergic Children
NCT02916446Phase 3Completed
- Sponsor
- DBV Technologies
- Start
- Oct 2016
- Primary completion
- Sep 2017
- Modality
- Transdermal Patches
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in peanut allergy comparing Viaskin Peanut 250 µg with Placebo (2 arms). Primary endpoint: Treatment-Emergent Adverse Events at 6 months. Started Oct 2016; status: completed.
02
Drugs
peanut protein
03
Conditions
peanut allergy
Beyond the preview
Go deeper on NCT02916446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02916446.